Hospital
Unitypoint Health - Marshalltown
Unitypoint Health - Marshalltown was paid $15.92M by Medicaid between Jan 2018 and Dec 2024, across 100 billing codes. Its largest line is 99284, emergency room visit (serious) — 27% of everything it billed.
33Billing provider infoUNITYPOINT HEALTH - MARSHALLTOWN
MARSHALLTOWN, IA 50158
MARSHALLTOWN, IA 50158
33aNPI1629503057assigned 04/24/2017
33bProvider typeGeneral Acute Care Hospital
28Total paid$15.92M
24GClaims252,335
24DCodes billed100
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Iowa
Rank by total paid#9 of 29
Median peer was paid$6.37M
This provider vs. median2.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 30,900 | $2.03M | |
| 2019 | 40,071 | $2.36M | |
| 2020 | 31,271 | $2.26M | |
| 2021 | 37,996 | $2.67M | |
| 2022 | 48,032 | $3.00M | |
| 2023 | 43,896 | $2.47M | |
| 2024incomplete | 20,169 | $1.12M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 27% | 15,142 | 14,173 | $4.34M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 24% | 11,127 | 10,105 | $3.84M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 14,044 | 13,411 | $2.73M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.1% | 6,484 | 5,835 | $971K |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.3% | 4,546 | 4,159 | $677K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 4.0% | 35,517 | 33,011 | $641K |
| A0427 | Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 2.5% | 6,160 | 5,084 | $405K |
| A0425 | Ground mileage, per statute mile | 2.5% | 12,066 | 8,846 | $392K |
| 71045 | Radiologic examination, chest; single view | 1.8% | 4,147 | 3,736 | $283K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.8% | 1,278 | 538 | $279K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.7% | 2,536 | 2,403 | $272K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 3,982 | 3,572 | $168K |
88 more codes
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 436 | $151K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,033 | $118K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,251 | $96K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,937 | $89K |
| 0240U | <1% | 604 | $75K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 673 | $58K |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | <1% | 772 | $49K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 382 | $44K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 252 | $44K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,690 | $33K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 241 | $26K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 388 | $16K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 686 | $15K |
| 87428 | <1% | 155 | $14K | |
| 76801 | <1% | 87 | $12K | |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 246 | $11K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 51 | $9K |
| 97597 | <1% | 97 | $8K | |
| 80053 | Comprehensive metabolic panel | <1% | 17,809 | $7K |
| 36415 | Collection of venous blood by venipuncture | <1% | 21,646 | $6K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 21,487 | $4K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 31 | $4K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 26 | $4K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 107 | $4K |
| 87400 | <1% | 2,013 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 182 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 75 | $3K |
| 59025 | Fetal non-stress test | <1% | 18 | $2K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 81 | $2K |
| 80061 | Lipid panel | <1% | 365 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 75 | $2K |
| 87631 | <1% | 46 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 66 | $2K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 12 | $1K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,366 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 751 | $1K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 16 | $723.68 |
| 81001 | <1% | 4,568 | $498.65 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,416 | $483.27 |
| 81003 | <1% | 2,682 | $415.30 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,174 | $313.58 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,408 | $223.32 |
| Q3014 | Telehealth originating site facility fee | <1% | 13 | $159.70 |
| 86850 | <1% | 12 | $145.10 | |
| 84484 | <1% | 5,292 | $111.08 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,483 | $101.16 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 17 | $91.74 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 623 | $84.37 |
| 82950 | <1% | 19 | $83.55 | |
| 83605 | <1% | 1,618 | $49.91 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,256 | $47.37 |
| 84703 | <1% | 1,443 | $44.19 | |
| 85027 | <1% | 369 | $43.05 | |
| 83690 | <1% | 3,100 | $31.09 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,668 | $25.81 |
| 86140 | <1% | 1,651 | $25.64 | |
| 82077 | <1% | 1,877 | $16.41 | |
| 80305 | <1% | 440 | $14.35 | |
| 87807 | <1% | 167 | $14.06 | |
| 85610 | <1% | 825 | $5.48 | |
| 83880 | <1% | 134 | $4.90 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 15 | $3.60 |
| 82962 | <1% | 105 | $3.12 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 44 | $1.62 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,953 | $1.48 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 40 | $0.02 |
| 84145 | 0% | 104 | $0.00 | |
| 80179 | 0% | 828 | $0.00 | |
| 80143 | 0% | 873 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 328 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 329 | $0.00 |
| 84100 | 0% | 32 | $0.00 | |
| 84702 | 0% | 38 | $0.00 | |
| 83735 | 0% | 584 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 230 | $0.00 |
| 87040 | 0% | 434 | $0.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 151 | $0.00 |
| 85730 | 0% | 114 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 63 | $0.00 |
| 82803 | 0% | 376 | $0.00 | |
| 85379 | 0% | 111 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 43 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 13 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 17 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 28 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 13 | $0.00 |
| 3044F | 0% | 16 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDELAGARDELLE, PAMELA (CEO)
| Provider | Location | Paid |
|---|---|---|
| Allen Memorial Hospital Corporation | Waterloo, IA | $21.93M |
| Allen Memorial Hospital Corporation | Waterloo, IA | $6.96M |
| Unitypoint Health - Marshalltown | Marshalltown, IA | $3.65M |
| Unitypoint Health - Marshalltown | Marshalltown, IA | $3.63M |
| Unitypoint Health - Marshalltown | Conrad, IA | $2.24M |
| Allen Memorial Hospital Corporation | Waterloo, IA | $2.14M |
| Unitypoint Health - Marshalltown | Toledo, IA | $1.47M |
| Unitypoint Health - Marshalltown | State Center, IA | $820K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.